Therefore, ANXA8 can better reflect the prognosis in patients with ovarian serous tumors, and its correlation with prognosis was even more pronounced in patients with poor differentiation, advanced FIGO stages, and TP53 mutations. Here, ANXA8 is linked to ovarian serous tumor.